Seeking Alpha

Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS...

Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS outlook to reflect the $37M redemption of convertible debt the medical device company announced earlier this week as well as reduced estimates for the U.S. spine market.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)